RenovoRx, Inc. (RNXT)
1.26
-0.02
(-1.56%)
USD |
NASDAQ |
Oct 12, 10:55
RenovoRx Enterprise Value : 48.67M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 48.67M |
| October 08, 2026 | 50.92M |
| October 07, 2026 | 52.73M |
| October 06, 2026 | 53.63M |
| October 05, 2026 | 57.24M |
| October 02, 2026 | 62.20M |
| October 01, 2026 | 60.85M |
| September 30, 2026 | 61.30M |
| September 29, 2026 | 61.75M |
| September 28, 2026 | 60.85M |
| September 25, 2026 | 65.81M |
| September 24, 2026 | 66.72M |
| September 23, 2026 | 64.46M |
| September 22, 2026 | 67.62M |
| September 21, 2026 | 66.26M |
| September 18, 2026 | 67.17M |
| September 17, 2026 | 68.97M |
| September 16, 2026 | 60.85M |
| September 15, 2026 | 68.52M |
| September 14, 2026 | 67.17M |
| September 11, 2026 | 70.33M |
| September 10, 2026 | 70.78M |
| September 09, 2026 | 80.93M |
| September 08, 2026 | 90.18M |
| September 04, 2026 | 98.75M |
| Date | Value |
|---|---|
| September 03, 2026 | 97.85M |
| September 02, 2026 | 104.62M |
| September 01, 2026 | 86.12M |
| August 31, 2026 | 78.00M |
| August 28, 2026 | 66.26M |
| August 27, 2026 | 57.69M |
| August 26, 2026 | 58.14M |
| August 25, 2026 | 54.98M |
| August 24, 2026 | 47.31M |
| August 21, 2026 | 50.47M |
| August 20, 2026 | 50.47M |
| August 19, 2026 | 50.25M |
| August 18, 2026 | 43.70M |
| August 17, 2026 | 45.06M |
| August 14, 2026 | 54.08M |
| August 13, 2026 | 47.76M |
| August 12, 2026 | 41.45M |
| August 11, 2026 | 42.80M |
| August 10, 2026 | 43.25M |
| August 07, 2026 | 41.45M |
| August 06, 2026 | 42.80M |
| August 05, 2026 | 38.74M |
| August 04, 2026 | 37.84M |
| August 03, 2026 | 38.74M |
| July 31, 2026 | 34.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 356.53M |
| Travere Therapeutics, Inc. | 5.037B |
| REGENXBIO, Inc. | 581.82M |
| Krystal Biotech, Inc. | 8.978B |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.911M |
| Revenue (Quarterly) | 0.909M |
| Total Expenses (Quarterly) | 3.82M |
| EPS Diluted (Quarterly) | -0.0616 |
| Gross Profit Margin (Quarterly) | 84.27% |
| Profit Margin (Quarterly) | -320.2% |
| Earnings Yield | -24.92% |
| Normalized Earnings Yield | -26.21 |